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Objectives: Previous work showed that gag-protease-derived phenotypic susceptibility to PIs differed between
HIV-1 subtype CRF02_AG/subtype G-infected patients who went on to successfully suppress viral replication ver-
sus those who experienced virological failure of lopinavir/ritonavir monotherapy as first-line treatment in a clinic-
al trial. We analysed the relationship between PI susceptibility and outcome of second-line ART in Nigeria, where
subtypes CRF02_AG/G dominate the epidemic.
Methods: Individuals who experienced second-line failure with ritonavir-boosted PI-based ART were matched
(by subtype, sex, age, viral load, duration of treatment and baseline CD4 count) to those who achieved virological
response (‘successes’). Successes were defined by viral load ,400 copies of HIV-1 RNA/mL by week 48. Full-
length Gag-protease was amplified from patient samples for in vitro phenotypic susceptibility testing, with PI
susceptibility expressed as IC50 fold change (FC) relative to a subtype B reference strain.
Results: The median (IQR) lopinavir IC50 FC was 4.04 (2.49–7.89) for virological failures and 4.13 (3.14–8.17) for
virological successes (P"0.94). One patient had an FC.10 for lopinavir at baseline and experienced subsequent
virological failure with ritonavir-boosted lopinavir as the PI. There was no statistically significant difference in
single-round replication efficiency between the two groups (P"0.93). There was a moderate correlation be-
tween single-round replication efficiency and FC for lopinavir (correlation coefficient 0.32).
Conclusions: We found no impact of baseline HIV-1 Gag-protease-derived phenotypic susceptibility on out-
comes of PI-based second-line ART in Nigeria.
Introduction
Prevalence of virological failure for first-line antiretroviral therapy
can be as high as 30%,1 with high-level resistance to NNRTI, teno-
fovir and cytosine analogues common in resource-limited settings
and compounded by prior undisclosed ART.2,3 Second-line ART rec-
ommended by WHO comprises a ritonavir-boosted PI and two
NRTIs, commonly lopinavir or atazanavir.4 PIs are the second- and
last-line therapy for the majority of HIV-infected patients world-
wide as access to third-line therapy is still limited.5 Virological fail-
ure with PIs as second-line therapy occurs in around 20% of
individuals.6–8 In contrast to first-line therapy, with which .80%
develop drug resistance mutations, only around 10%–20% de-
velop major resistance mutations to PIs by week 48,6,7,9,10 and this
proportion increases over time.5
It is known that proteins such as Gag and Env can affect suscep-
tibility to PIs even in the absence of known major resistance muta-
tions in the protease gene.11–15 There are limited data on changes
in gag following treatment failure with PIs in the non-B subtypes
that dominate low- and middle-income countries.15–20 It appears
that in around 15% of patients failing boosted PI (bPI) without major
protease mutations, a decrease in phenotypic susceptibility to the
drug appears to occur when gag-protease is phenotyped.21–23
Therefore it is conceivable that underlying phenotypic susceptibility
resulting from variation in genes such as gag and env might impact
clinical responses to PI.
We previously showed that gag-protease-derived phenotypic
susceptibility differed between CRF02_AG and subtype G-infected
patients who went on to successfully suppress viral replication
VC The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.
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versus those who experienced virological failure (VF) of lopinavir/
ritonavir monotherapy as first-line treatment in a clinical trial.12 In
order to determine the relevance of this finding for real-world set-
tings in the context of tenofovir disoproxil fumarate! lamivudine
or zidovudine! lamivudine with ritonavir-boosted PI (lopinavir or
atazanavir) we analysed the relationship between PI susceptibility
and the outcome of PI-based second-line ART in Nigeria, where
subtypes CRF02_AG and G dominate the epidemic.24
Patients and methods
Study participants
This study involved retrospectively testing samples from patients
attending for HIV care at University of Abuja Teaching Hospital (UATH)
who experienced second-line failure (HIV-1 RNA .1000 copies/mL
after .6 months on treatment) on a lopinavir/ritonavir- or atazanavir/
ritonavir-containing regimen, without any major PI mutations, who
were selected as ‘cases’. They were matched to ‘controls’, who had
achieved virological suppression lasting up to 12 months (HIV-1 RNA
,400 copies/mL) with a similar age, sex, baseline CD4 count and dur-
ation of treatment. Baseline (pre-PI) plasma samples from these
matched pairs were retrospectively retrieved.
Amplification of full-length gag-protease genes
HIV-1 RNA was manually extracted from archived plasma samples
using the QIAamp viral RNA extraction kit. Using previously described
techniques,11,25 full-length gag-protease was amplified and cloned
into a subtype B-based (p8.9NSX!) vector. Clonal sequencing of up to
10 plasmids (where possible) was performed by standard Sanger
sequencing. The variant that most closely represented the consensus
(obtained via next-generation sequencing as previously described6)
was taken forward for phenotypic testing. Sequences were manually
analysed using DNA dynamo software (http://www.bluetractorsoft
ware.co.uk) and MEGA v7.0 software.26 Protease sequences were ana-
lysed for PI resistance mutations using the Stanford Resistance
Database (https://hivdb.stanford.edu).
PI susceptibility and infectivity assays
PI susceptibility and viral infectivity were determined using a previously
described single assay. Briefly, 293T cells were co-transfected with a Gag-
Pol protein expression vector (p8.9NSX!) containing cloned patient-derived
gag-protease sequences, pMDG expressing vesicular stomatitis virus enve-
lope glycoprotein (VSV-g), and pCSFLW (expressing the firefly luciferase re-
porter gene with HIV-1 packaging signal).
PI drug susceptibility testing was carried out as previously described.25
Transfected cells were seeded with serial dilutions of lopinavir and har-
vested pseudovirions were used to infect fresh 293T cells. To determine
strain infectivity, transfected cells were seeded in the absence of drug.
Infectivity was monitored by measuring luciferase activity 48 h after infec-
tion. Results derived from at least two independent experiments (each in
duplicate) were analysed. The IC50 was calculated using GraphPad Prism 5
(GraphPad Software Inc., La Jolla, CA, USA). Susceptibility was expressed as
a fold change in IC50 compared with the subtype B reference strain
(p8.9NSX!). Replicative capacity of these viruses was assessed by compar-
ing the luciferase activity of recombinant virus with that of the WT subtype
B control virus in the absence of drug. Equal amounts of input plasmid DNA
were used, and it has previously been shown that percentage infectivity
correlates well with infectivity/ng p24 in this system.25 The PI drugs used in
this study were obtained from the AIDS Research and Reference Reagent
Program, Division of AIDS, NIAID, NIH.
Ethics
Informed consent was obtained from all subjects and ethics approval for
virological testing was obtained from the National Research Ethics
Committee of Nigeria (NHREC/01/01/2007).
Statistical analysis
Differences in PI susceptibility were compared with the Wilcoxon rank-sum
test (GraphPad Software Inc., La Jolla, CA, USA), which is robust to data that
are not normally distributed.
Results
Six matched pairs of patients were included. Table 1 contains clin-
ical and laboratory data on cases, who experienced virological fail-
ure (duration), and controls, who suppressed viral replication for
48 weeks. Of note, all pairs but one had a CD4 count ,200 cells/
mm3. All but one pair was treated with lopinavir-based ART (ataza-
navir was used in one pair). Table 2 shows NRTI and NNRTI resist-
ance mutations detected prior to second-line initiation. All patients
had lamivudine resistance [M184V/I in reverse transcriptase (RT)]
and 7/12 (58.3%) had at least moderate resistance to tenofovir (3
with K65R, 3 with K70E and 1 with three thymidine analogue
mutations including M41L, L210W and T215Y). All 12 individuals
had high-level NNRTI resistance. Two pairs were infected with sub-
type G viruses and four pairs with CRF02_AG viruses (Table 2). No
major mutations in protease were observed in the patients. We
analysed sequences for mutations in Gag in cases and controls
associated with PI susceptibility or exposure (Table 3).
The median (IQR) lopinavir fold change (FC) was 4.04 (2.49–
7.89) for virological failures and 4.13 (3.14–8.17) for virological suc-
cesses (P"0.94), as described in Figure 1(a). The median (IQR) ata-
zanavir FC was 2.43 (1.35–9.66) for virological failures and 4.39
(1.60–7.73) for successes (P"0.47). The median (IQR) darunavir
FC was 1.234 (0.84–2.05) for virological failures and 1.529 (1.14–
2.319) for successes (P"0.47).
One patient had an FC.10 for lopinavir at baseline and experi-
enced subsequent virological failure on boosted lopinavir as the PI.
We also measured the single-round replication efficiency of
patient-derived gag-protease-containing pseudoviruses derived
prior to initiation of second-line boosted PI treatment from
patients who either did (success) or did not (failure) suppress viral
replication after 48 weeks (Figure 1b). Mean replication efficiency
relative to a subtype B reference strain was 117.7% for the suc-
cesses and 105.8% for failures. There was no statistically signifi-
cant difference in replication efficiency between the two groups
(P"0.93 by Mann–Whitney U-test).
Finally, we analysed the relationship between single-round rep-
lication efficiency and FC to lopinavir in all viruses tested. There
was a moderate correlation between these parameters (correl-
ation coefficient 0.32, Figure 2). When a single outlier was
excluded from analysis (FC 10.7 with replication efficiency 50.0%),
the correlation coefficient increased to 0.78.
Discussion
Given the contribution of the highly polymorphic Gag protein and
resulting epistatic interactions to PI susceptibility, we hypothesized
that patients would respond differently to these drugs, particularly
Gag-protease phenotypic drug susceptibility to PIs JAC
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in the context of extensive NRTI resistance. We previously reported
an association between susceptibility to PI and outcome of first-
line ritonavir-boosted lopinavir monotherapy in a clinical trial. Here
we performed a similar study in patients about to start second-line
combination ART, including ritonavir-boosted lopinavir or atazana-
vir as well as two NRTIs. We found the difference in phenotypic
drug susceptibility (assessed by FC relative to a subtype B refer-
ence) was not statistically different between the virological failures
(cases) and virological successes (controls) for any of the PIs
tested: lopinavir, atazanavir or darunavir.
This negative result could be due to the influence of adherence,
in that second-line therapy is used in patients for whom first-line
therapy has failed, usually as the result of incomplete adherence.
Therefore, the patient group was enriched for poor adherers,
which could have overcome the effects of small differences in
susceptibility.
Interestingly, we previously showed that 2/2 patients with FC.10
prior to PI monotherapy went on to virological failure.27 In this study
the only patient with FC .10 for lopinavir failed treatment with this
drug. Further work needs to be undertaken to explore whether a
threshold FC of 10 in our assay is relevant in larger datasets.
We also showed here that replication efficiency over a single
round was correlated with lopinavir susceptibility prior to initiation
of the bPI. We have previously reported similar findings in
replication-competent subtype C viruses that contained patient-
derived gag and partial protease genes.12 These data suggest that
Table 1. Clinical data for matched patient pairs comprising virological successes and failures
Sample
pair
Age (years) Sex
Baselinea CD4 count
(cells/mm3)
Second-line
PI used
Baselinea viral load
(copies of HIV-1 RNA/mL)
success failure success failure success failure success failure success failure
1 33 45 female female ,200 ,200 LPV LPV 503 951 140 991
2 43 36 female female ,200 ,200 LPV LPV 39 844 20 178
3 27 26 female female ,200 ,200 LPV LPV 32 284 271 974
4 47 39 female female 200–499 200–499 LPV LPV 228 083 24 693
5 35 40 female female ,200 ,200 ATV ATV 14 487 274 504
6 34 33 female female ,200 ,200 LPV LPV 39 929 18 056
LPV, lopinavir; ATV, atazanavir.
aBaseline refers to pre-initiation of second-line therapy.
Table 2. NRTI and NNRTI mutations observed at first-line failure, prior to initiation of second-line PI-based ART
NRTI mutations NNRTI mutations
Baselinea VL (copies
of HIV-1 RNA/mL) HIV-1 subtype 2L backbone
success failure success failure success failure
Pair 1 success M41L, L74LI,
M184V, L210W, T215F
K101E, E138Q, G190A 503 951 140 991 CRF02_AG CRF02_AG TDF/FTC TDF/FTC
failure M184V K103N
Pair 2 success E44D, D67N, T69D,
K70R, M184V, T215Y
K101E, K103N 39 844 20 178 CRF02_AG CRF02_AG TDF/FTC TDF/FTC
failure M184V K101E, G190A
Pair 3 success K70E, M184V A98G, Y181C 32 284 271 974 G G TDF/FTC TDF/FTC
failure K70E, M184V Y181C, G190A, H221Y
Pair 4 success K70E, Y115F, M184V K103N 228 083 24 693 CRF02_AG CRF02_AG AZT/3TC AZT/3TC
failure K65R, M184V K101E, V108I, Y181C,
G190A
Pair 5 success D67N, K70R, M184V,
T215F, K219E
Y188C 14 487 274 504 G G TDF/FTC TDF/FTC
failure K70R, M184V, K219Q K103N, Y318F
Pair 6 success K65R, M184I K103N, Y181C 39 929 18 056 CRF02_AG CRF02_AG TDF/FTC TDF/FTC
failure K65R, M184I K103N, Y181C
AZT, zidovudine; 3TC, lamivudine; FTC, emtricitabine; TDF, tenofovir disoproxil fumarate.
aBaseline refers to pre-initiation of second-line therapy.
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increased replicative capacity and resistance to PI might involve an
overlapping mechanism.
Limitations
Limitations of our study include the relatively small sample
size, the inclusion of more than one subtype and the possibility
of viral recombination through our PCR and cloning strategy.
In addition, the process of mapping next-generation
sequencing reads to a consensus reference sequence to gen-
erate a patient consensus can introduce biases against vari-
ation, which may affect the identification of novel drug
resistance mutations. Finally, our assay system did not incorp-
orate the native gp160 envelope.
Despite introduction of second-generation integrase inhibitors
such as dolutegravir as first-line therapy in areas where
pre-treatment resistance is .10%,28,29 bPI will still be used as
second-line therapy for those who fail dolutegravir-based first-line
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Figure 1. (a) PI susceptibility relative to a subtype B reference strain, expressed as FC in IC50, and (b) single-round replication efficiency (relative to a
subtype B reference strain) of patient-derived gag-protease-containing pseudoviruses derived from patients prior to initiation of second-line boosted
PI treatment who either did (Success) or did not (Failure) suppress viral replication after 48 weeks. Each data point is the mean of at least two inde-
pendent experiments and hairs represent mean and SD. LPV, lopinavir; ATV, atazanavir; DRV, darunavir.
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regimens. Therefore, research into determinants of responses to PI
in non-B subtypes is as important as ever.
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